Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
In a head-to-head open-label trial reported in February 2026, average weight loss at 84 weeks favored tirzepatide, and the sponsor noted CagriSema did not meet its prespecified non-inferiority target against tirzepatide
Community planning typically uses 4-8 week cycles to allow time for skin or hair changes to become visible
Clinicians should evaluate for contraindications specific to GLP-1 receptor agonists, including: Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 History of pancreatitis or gallbladder disease Severe gastroparesis or gastrointestinal disease History of suicidal ideation or behavior Pregnancy or planned pregnancy (pregnancy testing when appropriate) Diabetic retinopathy (requires monitoring in patients with diabetes) Baseline investigations should include TSH, free T4, complete metabolic panel, lipid profile, and hemoglobin A1c (if diabetic or prediabetic)
